Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Under Armour Inc Class A (UAA) Price & Performance

Abeona Therapeutics IncTrade
Under Armour Inc Class ATrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Under Armour Inc Class A — how do they compare? Abeona Therapeutics Inc trades at $7.34 (market cap $421.19M), while Under Armour Inc Class A trades at $5.26 (market cap $2.26B). The key difference: Under Armour Inc Class A is far larger — about 5.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.

ABEOUAA
Market Cap
$421.19M$2.26B
Sector
HealthConsumer Cyclical
52-Week High
$7.45$8.14
52-Week Low
$4.17$4.17
Enterprise Value
$276.10M$3.24B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Under Armour Inc Class A

Under Armour (UAA) trades at $5.86, down 4.09% today, reflecting ongoing challenges. The stock shows a bearish technical trend with support near $5.00. Fundamentally, the company reported a net loss of -$201.27M in 2025 with a negative net margin of -9.99%, though recent Q2 2026 earnings beat expectations. Revenue declined to $5.16B in 2025, and cash flow turned negative at -$361.87M. Analyst sentiment is mixed with a consensus price target of $6.67 but a majority hold rating.

The outlook remains cautious due to weak North American demand and margin pressures. Investment opportunities exist if the company executes its full-price strategy successfully, but risks include persistent revenue declines and high debt levels. The stock's proximity to its low price target of $5.00 underscores downside vulnerability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Under Armour Inc Class A

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.

Read more on UAA